Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Completed 20 Terminated 2 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 35 Cisplatin 24 fludarabine 23 Radiotherapy 23 Paclitaxel 21 Carboplatin 20 pembrolizumab 18 Nivolumab 18 Magnetic Resonance Spectroscopy 18 Specimen Handling 17 fludarabine phosphate 15 Gemcitabine 15 Biopsy 15 Cytarabine 14 Radiation 11 Filgrastim 11 Doxorubicin 11 Docetaxel 11 Dexamethasone 11 Radiosurgery 10 Granulocyte Colony-Stimulating Factor 10 Etoposide 10 Melphalan 9 Ipilimumab 9 venetoclax 8 Rituximab 8 Calcium Dobesilate 8 trametinib 7 ibrutinib 7 durvalumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Withdrawn × tipifarnib × Clear all

NCT05693090 2023-03-06

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Kura Oncology, Inc.

Phase 1 Withdrawn

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡